US 12,331,264 B2
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
Daryl C. Drummond, Lincoln, MA (US); Dmitri B. Kirpotin, San Francisco, CA (US); Mark E. Hayes, Mill Valley, CA (US); Alexander Koshkaryev, Norwood, MA (US); and Ross B. Fulton, Southborough, MA (US)
Assigned to Akagera Medicines, Inc., Boxford, MA (US)
Filed by Akagera Medicines, Inc., Boxford, MA (US)
Filed on Aug. 8, 2022, as Appl. No. 17/818,052.
Application 17/818,052 is a continuation of application No. PCT/US2021/060877, filed on Nov. 24, 2021.
Claims priority of provisional application 63/118,534, filed on Nov. 25, 2020.
Prior Publication US 2022/0411394 A1, Dec. 29, 2022
Int. Cl. C11C 3/00 (2006.01); C07D 317/28 (2006.01); C07F 9/09 (2006.01)
CPC C11C 3/003 (2013.01) [C07D 317/28 (2013.01); C07F 9/091 (2013.01)] 20 Claims
 
1. An ionizable cationic lipid compound of the formula

OG Complex Work Unit Chemistry
wherein
a. each R22 is independently a linear polyunsaturated C16-C18 hydrocarbon lipid tail consisting of saturated alkyl groups on both ends of a pair of cis-oriented olefin double bonds separated by an unsaturated linear ethylene, n-propylene or n-butylene alkyl chain between the olefins within each R22 hydrocarbon chain; and
b.

OG Complex Work Unit Chemistry
 indicates attachment to a dialkyl amino alkyl group selected from the group consisting of: dimethylaminoethyl, diethylaminoethyl, and dimethylaminopropyl.